NCT07878975Recruiting
HRV Variation in Rheumatoid Arthritis
Heart Rate Variability as a Continuous Digital Biomarker for Flare Activity Monitoring and Flare Resolution in Rheumatoid Arthritis: A Pilot Study Using the Oura Ring
Source: ClinicalTrials.gov · Last updated 16 Oct 2026
Brief summary (registry, in English)
The goal of this observational study is to determine the association between continuous Heart Rate Variability (HRV) measured by the Oura ring and Rheumatoid Arthritis (RA) disease activity.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 30 (estimated)
- First submitted
- 9 Oct 2026
- Start date
- 1 Sept 2026
- Primary completion date
- 1 Sept 2027
- Lead sponsor
- University of Central Florida
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT07878975
What you commit to
- Study type: Observational
- Planned participants: 30
- From 1 Sept 2026 to the primary completion date, 1 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Atrial fibrillation or other clinically significant arrhythmias expected to invalidate HRV interpretation
- Recent major cardiovascular event within 6 months (e.g., myocardial infarction) or uncontrolled heart failure (NYHA class III-IV), per investigator judgment
Other
- Implanted pacemaker/defibrillator where HRV measurements are unreliable
- Severe autonomic dysfunction likely to interfere with HRV interpretation (e.g., advanced diabetic autonomic neuropathy), per investigator judgment
- Current use of beta-blockers (excluded due to known autonomic/HRV effects)
- Pregnancy or planned pregnancy during the study period
- Inability to wear the ring reliably (e.g., occupational restrictions or hand deformity preventing wear)
- Participation in another interventional clinical trial likely to confound outcomes
Who the study is looking for
- Diagnosis of RA meeting 2010 ACR/EULAR classification criteria
- Seropositive or seronegative RA eligible
- Any baseline disease activity (remission/low/moderate/high) to minimize selection bias
- Owns a compatible smartphone (iOS/Android) and is willing/able to use the Oura app
- Willing to wear Oura Ring during sleep throughout study participation (target adherence ≥5 valid nights/week)
- Willing to complete weekly remote assessments and attend baseline and three monthly routine follow-up visits
- Able to read and write English language
- Able to provide written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Central Florida Coordinator of this site? Confirm its status | Orlando | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.